The global pulmonary arterial hypertension (PAH) market is progressing at a high CAGR of 17.90% within a forecast period of 2014 to 2020. This market was recorded at US$4.04 bn in 2013, and is expected to reach US$5.19 bn by the end of 2020. The data is presented in a unique and comprehensive manner in a research report released by Transparency Market Research, titled “Pulmonary Arterial Hypertension (PAH) Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 – 2020.”
Pulmonary arterial hypertension is when the blood pressure inside the small arteries within the lungs increases. PAH can cause swelling of legs, fainting, dizziness, and shortness of breath, among other more serious symptoms. One of the biggest problems that a patient with PAH suffers is an extremely low tolerance to exercise. PAH can escalate into pulmonary vascular resistance and cause the failure of the right ventricle.
This 73 page report gives readers a comprehensive overview of the pulmonary arterial hypertension market. Browse through 14 data tables and 22 figures to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/pulmonary-arterial-hypertension-therapeutics.html
According to the report, the primary driver for the global PAH market is the list of newly-approved drugs and medical products aimed at treating PAH. A large number of medical products are already approved, while more are still in the pipeline. Another factor promoting the growth of the global PAH market is the increasing number of leaps taken in research and development efforts, aided by government policies and other initiatives.
The report provides a segmented analysis of the global PAH market. These segments are sorted within the categories of drug class and geography. The report also provides an extensive analysis of the pipeline drugs in the global PAH market.
In terms of drug class, the global PAH market is segmented into soluble guanylate cyclase (sGC) stimulators, phosphodiesterase-5 (PDE-5) inhibitors, endothelin receptor antagonists (ERAs), and prostacyclin and prostacyclin analogs. Of these, the report’s authors have put the prostacyclin and prostacyclin analogs segment ahead of the ERA segment, which means that the segment will lead the global PAH market by 2023, surpassing the current leader, ERAs.
The report’s geographical segmentation of the global PAH market reveals Asia Pacific to be the fastest-growing region for the given forecast period. The growth rate of this region is attributed to major opportunities that will be found in Australia, New Zealand, Japan, China, and India. Enterprises operating in these regions could take advantage of these opportunities and increase their profits and presence in the market.
Request a sample of this report to know what opportunities will emerge in the rapidly evolving pulmonary arterial hypertension market during 2014 – 2020: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1181
The report, however, states one of the major restraints on the global PAH market as the challenges faced by the Rest of the World PAH market. The report’s study shows that most of the nations in the Rest of the World region possess a low level of awareness of this market’s products. Therefore, this region is showing a much slower growth rate when compared to the regions of North America or Europe.
The key players in the global pulmonary arterial hypertension market are United Therapeutics Corp., Novartis International AG, Pfizer Inc., GlaxoSmithKline plc, Bayer HealthCare, Gilead Sciences Inc., and Actelion Pharmaceuticals Ltd.